Mankind Pharma

Mankind Pharma

2,466.00
+35.30
(1.45%)
Market Cap
1,00,322.00 Cr
EPS
49.28
PE Ratio
53.83
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
3,054.80
52 Week Low
2,115.10
PB Ratio
7.10
Debt to Equity
0.37
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from16 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+68.75 %
+68.75 %
Hold
Hold+18.75 %
+18.75 %
Sell
Sell+12.50 %
+12.50 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,639.80
#1 3,89,220.10
34.29
#1 54,729.00
9.71
#1 10,980
-19.84
46.24
6,100.50
1,58,245.80
70.26
9,712.00
18.67
2,191
26.74
35.70
1,561.00
1,22,900.80
23.40
28,409.50
7.12
5,291
9.88
62.21
3,617.80
1,22,723.70
60.63
11,539.40
6.99
1,911
19.91
57.51
1,253.40
1,01,842.70
#1 18.40
33,741.20
16.73
5,725
1.26
51.29
2,466.00
#6 1,00,322.00
#8 53.83
#7 12,744.20
#1 20.90
#8 2,007
#9 -18.14
43.32
988.60
96,160.80
21.35
23,511.00
18.55
4,615
2.60
57.92
1,989.80
88,772.50
24.56
22,909.50
13.74
3,306
#1 51.64
58.30
32,940.00
69,187.70
48.27
6,684.70
9.64
1,414
11.55
45.62
5,388.50
61,564.00
28.34
13,458.30
3.70
2,216
21.39
70.92

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
20.90 %
Net Income Growth
3.39 %
Cash Flow Change
12.12 %
ROE
-32.07 %
ROCE
-46.01 %
EBITDA Margin (Avg.)
5.21 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
1,764
2,200
2,457
2,130
2,103
2,642
2,772
2,682
2,517
2,976
3,189
3,286
3,333
3,653
Expenses
1,441
1,724
1,835
1,654
1,636
1,924
2,025
2,000
1,836
2,196
2,227
2,383
2,401
2,724
EBITDA
323
476
622
477
467
718
746
681
681
780
962
903
933
930
Operating Profit %
17 %
21 %
24 %
21 %
20 %
25 %
25 %
23 %
24 %
23 %
28 %
26 %
22 %
24 %
Depreciation
47
78
79
85
85
87
97
110
100
103
106
187
231
219
Interest
13
16
10
13
5
6
9
9
9
11
7
221
191
171
Profit Before Tax
263
382
533
379
377
625
641
562
572
666
849
495
511
541
Tax
70
84
110
83
84
130
130
103
95
123
190
111
86
96
Net Profit
193
298
423
296
294
494
511
460
477
543
659
385
425
445
EPS in ₹
4.74
7.30
10.48
7.09
7.13
12.15
12.51
11.33
11.76
13.39
16.31
9.46
10.19
10.62

Balance Sheet

Balance Sheet
2022
2023
2024
2025
Total Assets
9,148
9,715
11,963
27,760
Fixed Assets
3,588
4,251
4,545
19,005
Current Assets
4,407
4,328
6,568
6,988
Capital Work in Progress
702
550
282
826
Investments
1,110
1,346
2,568
2,042
Other Assets
3,749
3,568
4,568
5,887
Total Liabilities
9,148
9,715
11,963
27,760
Current Liabilities
2,624
1,863
2,120
5,664
Non Current Liabilities
208
229
268
7,528
Total Equity
6,316
7,623
9,576
14,568
Reserve & Surplus
6,115
7,395
9,323
14,291
Share Capital
40
40
40
41

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
2025
Net Cash Flow
103
-92
156
22
77
22
Investing Activities
-436
-1,222
-1,369
-1,052
-2,081
-12,624
Operating Activities
1,070
1,137
920
1,813
2,152
2,413
Financing Activities
-531
-8
605
-740
5
10,233

Share Holding

% Holding
Sept 2022
Mar 2023
May 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
79.00 %
76.50 %
76.50 %
76.50 %
76.50 %
76.50 %
74.88 %
74.87 %
74.87 %
72.71 %
72.70 %
72.68 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
9.87 %
11.58 %
12.37 %
13.34 %
12.92 %
13.07 %
DIIs
0.00 %
2.64 %
2.64 %
4.64 %
4.39 %
9.49 %
11.14 %
9.95 %
9.90 %
11.06 %
11.48 %
11.50 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
4.15 %
4.15 %
1.02 %
1.11 %
1.14 %
1.22 %
1.46 %
1.55 %
1.60 %
1.64 %
1.52 %
Others
21.00 %
16.71 %
16.71 %
17.83 %
18.00 %
12.87 %
2.89 %
2.15 %
1.31 %
1.30 %
1.26 %
1.23 %
No of Share Holders
17
4,02,322
4,02,322
1,31,918
1,34,731
1,27,449
1,35,116
1,53,450
1,63,854
1,72,431
1,80,597
1,79,549

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
08 Aug 2025 DIVIDEND Dividend
₹ 1.00 /share
08 Aug 2025 2,575.00 2,541.90
07 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
07 Aug 2025 2,386.35 2,553.25
31 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Jul 2025 2,578.00 2,575.00
21 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
21 May 2025 2,430.05 2,550.70
23 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jan 2025 2,738.25 2,515.05
05 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Nov 2024 2,506.95 2,734.95
09 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Aug 2024 2,114.50 2,068.60

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation2 days ago
Announcement under Regulation 30 (LODR)-Change in Management5 days ago
Shareholder Meeting / Postal Ballot-Scrutinizers Report5 days ago
Shareholder Meeting / Postal Ballot-Outcome of AGM6 days ago
Announcement under Regulation 30 (LODR)-Earnings Call Transcript7 days ago
Intimation For Submission Of Application For Reclassification10 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 01, 2025
Announcement Under Regulation 30- TDS Communication To The Shareholders.Jul 31, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportJul 31, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 31, 2025
Announcement under Regulation 30 (LODR)-RestructuringJul 31, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJul 31, 2025
Intimation Of Record DateJul 31, 2025
Corporate Action-Board approves DividendJul 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 31, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 31, 2025
Un-Audited Financial Results For The Quarter Ended On June 30 2025Jul 31, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On July 31 2025Jul 31, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 24, 2025
Intimation Of Receipt Of Request For ReclassificationJul 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 18, 2025
Intimation Of Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With Company Or DepositoriesJul 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 17, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 15, 2025
Reg. 34 (1) Annual Report.Jul 15, 2025
Notice Of 34Th Annual General Meeting Of Mankind Pharma LimitedJul 15, 2025
Closure of Trading WindowJul 14, 2025
Corporate Action-Board to consider DividendJul 14, 2025
Board Meeting Intimation for Unaudited Quarterly Financial Results & Interim DividendJul 14, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 04, 2025
Intimation Of The Date Of 34Th Annual General Meeting (AGM) Of The CompanyJul 03, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 10, 2025
Intimation Under Regulations 30 & 51 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Environmental Social And Governance (ESG) RatingJun 04, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJun 02, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 21, 2025
Appointment Of Cost Auditor And Secretarial AuditorMay 21, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMay 21, 2025
Outcome Of Board MeetingMay 21, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 21, 2025
Outcome Of Board MeetingMay 21, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 21, 2025

Technical Indicators

RSI(14)
Neutral
43.32
ATR(14)
Less Volatile
71.06
STOCH(9,6)
Oversold
14.99
STOCH RSI(14)
Oversold
7.16
MACD(12,26)
Bearish
-24.55
ADX(14)
Weak Trend
23.15
UO(9)
Bearish
37.76
ROC(12)
Downtrend But Slowing Down
-2.97
WillR(14)
Neutral
-77.73

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
SBI Large Cap Direct Plan-Growth
1.97%
1265875
0.76%
0.65%
SBI Mid Cap Direct Plan-Growth
0.00%
-1265873
-1.26%
-1.39%
Motilal Oswal Midcap Fund Direct-Growth
0.00%
-918589
-0.64%
-0.75%
Franklin India Opportunities Direct Fund-Growth
1.62%
465950
1.62%
1.62%
Bandhan Flexi Cap Fund Direct-Growth
0.00%
-375000
-1.14%
-1.17%
Franklin India Large Cap Fund Direct-Growth
0.00%
-310171
-0.90%
-1.00%
Edelweiss Mid Cap Direct Plan-Growth
0.50%
215679
0.50%
0.50%
Axis Multicap Fund Direct-Growth
1.07%
204587
0.67%
0.58%
Kotak Arbitrage Fund Direct-Growth
0.00%
-189450
-0.06%
-0.01%
Axis Large & Mid Cap Fund Direct-Growth
1.18%
186973
0.41%
0.33%
Edelweiss Large & Mid Cap Direct Plan-Growth
1.01%
159074
1.01%
1.01%
Franklin India Large & Mid Cap Fund Direct-Growth
0.00%
-146763
-0.92%
-1.04%
Baroda BNP Paribas Health and Wellness Fund Direct-Growth
5.51%
143843
5.51%
5.51%
Canara Robeco Mid Cap Fund Direct - Growth
1.01%
123487
1.01%
1.01%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
3.88%
-115019
-0.32%
2.26%
Aditya Birla Sun Life ELSS Tax Saver Direct-Growth
0.00%
-78841
-0.12%
-0.13%
Axis Large Cap Fund Direct-Growth
0.27%
-76124
-0.02%
-0.05%
Aditya Birla Sun Life Multi Asset Allocation Fund Direct-Growth
0.76%
74975
0.47%
0.43%
Axis India Manufacturing Fund Direct-Growth
0.80%
71091
0.40%
0.37%
Tata India Pharma & Healthcare Fund Direct-Growth
2.15%
70444
1.40%
1.32%
Mirae Asset Healthcare Fund Direct - Growth
1.80%
-67500
-0.46%
-0.69%
Invesco India Focused Fund Direct - Growth
3.83%
62257
0.68%
0.33%
Mahindra Manulife Multi Cap Fund Direct - Growth
0.28%
62000
0.28%
0.28%
HDFC Business Cycle Fund Direct - Growth
1.27%
-59993
-0.33%
-0.50%
ITI Mid Cap Fund Direct - Growth
0.00%
-54036
-1.00%
-1.11%

About Mankind Pharma

Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since expanded into animal healthcare, female infertility treatments, and oncology. The company operates 23 manufacturing facilities across India with a total installed capacity of 40.77 billion units as of March 31, 2022. In April 2023, Mankind Pharma went public through an Initial Public Offer. The company has acquired several subsidiaries and brands, and has expanded internationally with subsidiaries in the US, Singapore, Nepal, and UAE.
Listing Date
09 May, 2023(2 Years, 5 days)
Chairperson NameRAMESH CHAND JUNEJA